Estimates vary, but Invest India pegs the sector at roughly $14 billion today, growing toward $30 billion by 2030, with other projections running as high as $50.1 billion by 2030. Either way, India ranks as Asia's fourth-largest medical device market.
The catch? Getting in isn't simple. US companies face CDSCO regulations, unfamiliar entity structures, and compliance requirements that look nothing like the FDA process back home—often without any on-ground team to navigate them.
This guide breaks down the regulatory pathways, entry structures, and operational realities you need to plan for, plus how VJM Global helps US MedTech companies set up shop in India correctly the first time.
Key Takeaways
- Validate India MedTech market size at the product level—headline growth figures vary widely
- Treat CDSCO registration, entity structure, and a compliant local partner as non-negotiable
- Plan early for pricing caps, GST, and reimbursement rules that differ sharply from the US
- Use VJM Global for entity formation, tax, and payroll when setting up Indian operations
Understanding India's MedTech Regulatory Landscape
CDSCO regulates medical devices under the Drugs and Cosmetics Act, 1940 and the Medical Devices Rules, 2017 (MDR). Every device falls into one of four risk categories.
| India MDR 2017 | Risk Level | FDA Rough Comparison |
|---|---|---|
| Class A | Low risk | Similar to Class I |
| Class B | Low-moderate risk | No direct equivalent |
| Class C | Moderate-high risk | No direct equivalent |
| Class D | High risk | Similar to Class III |
Don't assume your FDA clearance means anything here. The FDA's Class I-III system doesn't map cleanly onto India's four-tier structure. Each SKU needs independent classification under MDR.
The Import Licensing Process
Foreign manufacturers file an application in Form MD-14 through the CDSCO's Sugam portal to obtain an MD-15 import licence. Non-sterile, non-measuring Class A devices are exempt from this licensing regime, but verify your product's exact attributes before relying on that exemption.
You'll also need an authorised Indian agent to file on your behalf. Exact power-of-attorney requirements should be confirmed case by case with a compliance professional, since generic templates rarely hold up to scrutiny.
BIS Certification and Timelines
BIS certification is technically voluntary, but the government can make compliance with Indian standards mandatory through Quality Control Orders (QCOs) for specific product categories. Check whether your device falls under an active QCO before assuming certification is optional.
Timeline reality: No universal processing window exists in CDSCO's public documentation. Delays typically stem from:
- Incomplete technical documentation
- Missing or improperly formatted agent authorizations
- Classification disputes requiring additional queries
Budget generously and start documentation early. This is one area where "figure it out as you go" gets expensive.
Choosing the Right Market Entry Structure
Your entry structure shapes everything downstream, from control over branding to how fast you can hire.
| Structure | Speed | Control | Compliance Burden |
|---|---|---|---|
| Distributor/Importer | Fastest | Low | Minimal |
| Liaison Office | Moderate | Limited to permitted activities | Moderate |
| Joint Venture | Moderate | Shared | Moderate-high |
| Wholly Owned Subsidiary | Slower | Full | High |
Most US MedTech firms choose between a distributor model and a wholly owned subsidiary. Liaison offices and joint ventures sit between those poles on speed, control, and compliance.
Distributor vs. Subsidiary
Working through a distributor or importer gets you into the market fastest, using the same MD-14 to MD-15 import route discussed above. You avoid heavy upfront investment, but you sacrifice control over pricing, customer data, and brand positioning.
A wholly owned subsidiary (WOS) gives you full control over operations, inventory, hiring, and licensing. The tradeoff is a real compliance footprint: ROC filings, GST registration, transfer pricing documentation, and ongoing statutory obligations.
What determines your choice?
- Company size: Smaller firms often start with a distributor, then convert later
- Product complexity: Devices requiring in-country servicing or clinical support favour a subsidiary
- Growth ambitions: If India is a five-year strategic market, not a pilot, build the subsidiary early
VJM Global's entity formation process for foreign companies handles this end-to-end:
- Securing Digital Signature Certificates and Director Identification Numbers
- Reserving your company name through SPICe+
- Filing the Memorandum and Articles of Association with the Registrar of Companies
- Obtaining your Certificate of Incorporation
Indian law requires at least two directors (one resident in India) and two shareholders for a subsidiary.
Reimbursement, Pricing, and Market Access Considerations
Forget the fragmented US payer landscape. India's National Pharmaceutical Pricing Authority (NPPA) sets hard price ceilings on certain device categories.
Case in point: A February 2026 NPPA notification set coronary stent ceilings at ₹10,692.69 for bare-metal stents and ₹38,933.14 for drug-eluting stents, plus applicable GST. Manufacturers, marketers, and importers must sell within these caps across the entire country.
Screen every product category for NPPA exposure before finalizing pricing. A margin model built on US assumptions will collapse fast if your device falls under a Schedule I price cap.
Price caps only matter if you can reach the buyer. In India, that path splits sharply by channel.
Sales Channels Differ Fundamentally
- Government hospitals and tenders: Price-sensitive and procurement-driven; often need local registration and public-body compliance documents
- Private hospital chains: More pricing flexibility, but expect clinical validation and sustained relationship-building
Overall insurance penetration in India sits at just 3.7%, so self-pay and hospital financing still drive much of device adoption today.
Plan for these channels separately. A device that works in metro private hospitals may need a completely different pricing and distribution approach for government tenders.
Tax, Compliance, and Ongoing Operational Requirements
Once your entity is live, the compliance clock starts running immediately.
GST and import duties:
- Most medical devices attract 5% GST; confirm the HSN code and notification before you invoice
- Customs duty varies by product classification; there's no universal import-duty rate, so confirm the eight-digit tariff code for each device
Ongoing annual obligations:
- ROC annual filings, director disclosures, and statutory register updates under the Companies Act
- GST return filing, input-output reconciliation, and annual GSTR-9C compliance for turnover above ₹2 crore
- TDS compliance and income-tax return filing
Managing all this from a US headquarters without local staff often leads to missed deadlines.
VJM Global's back-office support covers payroll, accounting, and tax compliance so US companies can hire in India without building a finance team from scratch. That includes statutory contributions and employee tax withholding, freeing your team to focus on clinical adoption and sales.
Building Distribution and Commercial Partnerships
Your distributor is your face in the market. Choose poorly, and you inherit their reputation.
Vet distributors on:
- Regulatory compliance track record with CDSCO
- Existing hospital network reach and depth
- Financial stability and inventory management capacity
- References from other international device manufacturers they've represented
Beyond distribution, local key opinion leaders (KOLs) are central to clinical credibility. Indian physicians and hospital administrators trust peer validation over marketing claims. A well-placed KOL relationship can shortcut months of trust-building.
Pair those relationships with a phased commercial rollout so early placements build both clinical proof and partner confidence:
Recommended rollout sequence:
- Launch in metro hospital networks (Delhi, Mumbai, Bangalore) where infrastructure and clinical sophistication are highest
- Build case studies and clinical evidence from these early placements
- Expand to tier-2 cities once you have proof points and a stable distribution partner
Deloitte India research shows hospital leaders are increasingly focused on tier-2 and tier-3 expansion, with 60% of hospital CXOs expecting 10-15% sector growth in the coming year. That demand is real—but sustainable expansion still follows metro proof points, not the reverse.
How VJM Global Supports US MedTech Companies Entering India
Navigating CDSCO, FEMA, and ROC requirements simultaneously is a lot to ask of a US team with no India presence. That's the gap VJM Global fills.
Capabilities that help US MedTech companies enter India include:
- Entity structure selection and FDI-permissibility assessment before you incorporate
- Full incorporation processing: DSC, DIN, name reservation, MoA/AoA drafting, ROC filings
- PAN, TAN, and GSTIN registration
- Ongoing GST filing, ROC compliance, and statutory audit support
- Payroll management and India-specific employment compliance
- FEMA/FDI advisory and RBI reporting for foreign investment inflows
With 30+ years of experience and a track record serving 500+ American business owners, VJM Global delivers this support using India's own regulatory instruments, not a generic global template. That local approach reduces the guesswork that typically slows foreign entrants and shortens time-to-market.
Whether you're weighing a distributor relationship or ready to incorporate a subsidiary, getting the structure and compliance foundation right from day one saves significant rework later.
Frequently Asked Questions
Is MedTech in demand in the USA?
Yes. US demand for medical devices remains strong and growing. Saturated home markets are why many manufacturers expand into high-growth markets such as India.
What are the key trends in medical devices for 2026?
Digital health, AI-enabled diagnostics, and remote monitoring are reshaping the industry globally. In India, these trends are gaining traction as hospitals invest in tech-driven care, though full AI integration is still years away due to regulatory requirements.
What are the 5 P's of healthcare marketing?
Product, price, place, promotion, and people. For medical devices in India, this means adapting pricing to NPPA caps, choosing the right distribution channels, and building trust through clinical relationships (people).
What licenses are required to sell medical devices in India?
You'll need a CDSCO import license (via MD-14/MD-15 filing) and, depending on the product, BIS certification under an applicable Quality Control Order. An authorised Indian agent must file on your behalf.
Can a foreign MedTech company own 100% of an Indian entity?
Yes. Under India's FDI policy, 100% foreign ownership is permitted under the automatic route for manufacturing medical devices in most categories. This doesn't eliminate the need for separate CDSCO licensing.
How long does it take to register a medical device with CDSCO?
There is no fixed universal timeline. It depends on device classification, documentation completeness, and how quickly you answer CDSCO queries. Complete technical files move faster than incomplete ones.
